This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Homicsko, K. Articles by Iggo, R. D. Search for Related Content PubMed PubMed Citation Articles by Homicsko, K. Articles by Iggo, R. D.

RAD001 (Everolimus) Improves the Efficacy of Replicating Adenoviruses that Target Colon Cancer

National Center of Competence in Research Molecular Oncology, Swiss Institute for Experimental Cancer Research (ISREC), Epalinges, Switzerland

Requests for reprints: Richard Iggo, Oncogene Group, Swiss Institute for Experimental Cancer Research, Ch. des Boveresses 155, CH-1066 Epalinges, Switzerland. Phone: 41-21-692-5889; Fax: 41-21-652-6933; E-mail: Richard.Iggo{at}isrec.ch.

Selectively replicating adenoviruses have the potential to cure cancer but have shown little efficacy in clinical trials. We have tested the ability of the mTOR kinase inhibitor RAD001 (everolimus) to enhance the response of xenografts to an oncolytic adenovirus. The virus has Tcf sites inserted in the early viral promoters and replicates selectively in cells with activation of the Wnt signaling pathway. To enhance tumor cell infection, an integrin targeting peptide (CDCRGDCFC) was inserted into the fiber gene of the virus. RAD001 combines three useful properties: it inhibits tumor cell growth directly, blocks angiogenesis, and suppresses the immune response. RAD001 does not block viral protein expression, DNA replication, or cytopathic effect in tumor cells in vitro. After 6 weeks of daily RAD001 treatment, ongoing viral DNA replication could be detected in tumor xenografts, showing that RAD001 does not inhibit virus replication in vivo. I.v. injection of virus alone produced a small delay in xenograft growth, whereas combination therapy substantially prolonged the survival of the mice. We suggest that collapsing the tumor vasculature after the initial infection traps the virus and facilitates local spread within the tumor. Unlike conventional drugs, which require continued access to the tumor through the vascular system, oncolytic viruses are in principle less sensitive to late reductions in perfusion because they are produced locally within the tumor.

This article has been cited by other articles:

				I. Peerlinck, S. Amini-Nik, R. K. Phillips, R. Iggo, N. R. Lemoine, S. Tejpar, and G. Vassaux Therapeutic Potential of Replication-Selective Oncolytic Adenoviruses on Cells from Familial and Sporadic Desmoid Tumors Clin. Cancer Res., October 1, 2008; 14(19): 6187 - 6192. [Abstract] [Full Text] [PDF]

				G. M. Funston, S. E. Kallioinen, P. de Felipe, M. D. Ryan, and R. D. Iggo Expression of heterologous genes in oncolytic adenoviruses using picornaviral 2A sequences that trigger ribosome skipping J. Gen. Virol., February 1, 2008; 89(2): 389 - 396. [Abstract] [Full Text] [PDF]

				T. Kuroda, S. D. Rabkin, and R. L. Martuza Effective Treatment of Tumors with Strong {beta}-Catenin/T-Cell Factor Activity by Transcriptionally Targeted Oncolytic Herpes Simplex Virus Vector. Cancer Res., October 15, 2006; 66(20): 10127 - 10135. [Abstract] [Full Text] [PDF]